The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://blancheehgn662505.thecomputerwiki.com/6122103/glp_3_retatrutide_a_comparative_analysis